Venus Medtech (Hangzhou) Inc. (VMTHF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Venus Medtech (Hangzhou) Inc. (VMTHF) trades at $0.42 with AI Score 57/100 (Grade B). Venus Medtech (Hangzhou) Inc. specializes in developing and commercializing transcatheter heart valve medical devices, addressing critical cardiovascular conditions. Market cap: $186.06M, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for VMTHF: VMTHF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VMTHF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
VMTHF: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
Venus Medtech (Hangzhou) Inc. (VMTHF) Healthcare & Pipeline Overview
Venus Medtech (Hangzhou) Inc. focuses on the development and commercialization of transcatheter heart valve technologies, including aortic and pulmonary valves, and cerebral embolic protection devices. Operating primarily in Mainland China and internationally, the company addresses significant cardiovascular needs with innovative medical solutions, facing competition in a specialized medical device market.
What Is the Investment Thesis for VMTHF?
Venus Medtech (Hangzhou) Inc. presents a focused investment opportunity within the growing market for minimally invasive heart valve therapies. The company's established presence in China, coupled with its expanding product portfolio, positions it to capitalize on the increasing demand for advanced cardiovascular treatments. A key value driver is the continued adoption of TAVR procedures and the expansion into new therapeutic areas such as mitral and tricuspid valve interventions. However, the company's negative profit margin of -150.4% indicates ongoing challenges in achieving profitability. Upcoming catalysts include the potential regulatory approvals and commercial launches of VenusA-Plus and VenusA-Pilot. Potential risks include intense competition, regulatory hurdles, and the need for continued innovation to maintain a competitive edge. Investors should closely monitor the company's progress in achieving profitability and expanding its market share.
Based on FMP financials and quantitative analysis
VMTHF Key Highlights
- Venus Medtech operates in the high-growth transcatheter heart valve market, driven by increasing demand for minimally invasive cardiovascular procedures.
- The company's VenusA-Valve is a key product for treating severe aortic stenosis, addressing a significant patient population in China and internationally.
- Venus Medtech's expansion into pulmonary valve therapies with VenusP-Valve diversifies its product portfolio and targets additional cardiovascular conditions.
- The company's negative P/E ratio of -1.39 reflects current losses but also indicates potential for future earnings growth if profitability improves.
- With a gross margin of 75.8%, Venus Medtech demonstrates strong potential for profitability as it scales its operations and reduces operating expenses.
Who Are VMTHF's Competitors?
VMTHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BCCOY BICO Group AB (publ) | $0.50 | +0.00% | $141.15M | 46 |
| CLLKF BICO Group AB (publ) | $1.76 | -7.36% | $121.71M | 47 |
| DMTRF 3-D Matrix, Ltd. | $2.25 | +0.00% | $270.48M | 66 |
| IMPZY Implanet S.A. | $0.08 | +0.00% | $229.26M | 53 |
| JUSHF Jushi Holdings Inc. | $0.48 | -2.16% | $95.06M | 41 |
| NPCE NeuroPace, Inc. | $15.89 | +0.32% | $541.75M | 65 |
| ATRWF Altius Renewable Royalties Corp. | $8.50 | +0.00% | $262.46M | 64 |
| LFTSF LifeTech Scientific Corporation | $0.23 | +0.00% | $1.03B | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VMTHF's Key Strengths?
- Innovative transcatheter heart valve technologies.
- Strong presence in the Chinese market.
- Expanding product portfolio.
- Experienced management team.
What Are VMTHF's Weaknesses?
- Negative profit margin.
- Limited international presence compared to larger competitors.
- Reliance on key products.
- OTC market listing.
What Could Drive VMTHF Stock Higher?
- Regulatory approval and commercial launch of VenusA-Plus, the next-generation TAVR system.
- Expansion into new geographic markets, particularly in emerging economies.
- Continued adoption of VenusA-Valve and VenusP-Valve in clinical practice.
- Development of transcatheter mitral and tricuspid valve replacement therapies.
- Strategic partnerships and acquisitions to expand product portfolio and market reach.
What Are the Key Risks for VMTHF?
- Intense competition from established medical device companies.
- Regulatory hurdles and approval delays for new products.
- Technological obsolescence and the need for continuous innovation.
- Negative profit margin and the need to achieve profitability.
- Risks associated with operating in the Chinese market, including regulatory and economic uncertainties.
What Are the Growth Opportunities for VMTHF?
- Expansion into New Geographic Markets: Venus Medtech has the opportunity to expand its geographic footprint beyond Mainland China. Targeting emerging markets with growing healthcare infrastructure and an increasing prevalence of cardiovascular diseases could significantly boost revenue. This expansion requires strategic partnerships, regulatory approvals, and tailored marketing strategies. The global market for heart valve replacement is projected to reach $10 billion by 2028, providing a substantial opportunity for Venus Medtech to capture market share.
- Development of Next-Generation TAVR Products: The company's ongoing development of VenusA-Plus and VenusA-Pilot represents a significant growth opportunity. These next-generation TAVR systems aim to improve clinical outcomes, expand the treatable patient population, and enhance ease of use. Successful development and commercialization of these products could solidify Venus Medtech's position in the TAVR market. The timeline for regulatory approval and commercial launch is estimated at 2-3 years, pending clinical trial results and regulatory review.
- Expansion into Mitral and Tricuspid Valve Therapies: Venus Medtech is exploring transcatheter solutions for mitral and tricuspid valve replacement, addressing a significant unmet clinical need. The market for mitral and tricuspid valve therapies is estimated to be even larger than the aortic valve market, offering substantial growth potential. The development of effective and safe transcatheter mitral and tricuspid valve therapies could transform the treatment of these conditions and drive significant revenue growth for Venus Medtech.
- Leveraging TriGUARD3 for Cerebral Embolic Protection: The TriGUARD3 device offers a unique opportunity for Venus Medtech to address the risk of cerebral embolism during TAVR procedures. By promoting the use of TriGUARD3 in conjunction with its TAVR systems, the company can enhance the safety and efficacy of its procedures, attracting more patients and clinicians. The market for cerebral embolic protection devices is growing, driven by increasing awareness of the importance of preventing stroke during cardiovascular interventions.
- Strategic Partnerships and Acquisitions: Venus Medtech can pursue strategic partnerships and acquisitions to expand its product portfolio, access new technologies, and enter new markets. Collaborating with other medical device companies or acquiring complementary technologies could accelerate the company's growth and enhance its competitive position. Potential targets include companies specializing in cardiac imaging, electrophysiology, or other cardiovascular specialties.
What Opportunities Does VMTHF Have?
- Expansion into new geographic markets.
- Development of next-generation TAVR products.
- Growth in the mitral and tricuspid valve therapy market.
- Strategic partnerships and acquisitions.
What Threats Does VMTHF Face?
- Intense competition from established medical device companies.
- Regulatory hurdles and approval delays.
- Technological obsolescence.
- Economic downturns affecting healthcare spending.
What Are VMTHF's Competitive Advantages?
- Proprietary transcatheter heart valve technologies.
- Established presence in the Chinese market.
- Strong relationships with key opinion leaders and clinicians.
- Growing portfolio of innovative cardiovascular solutions.
What Does VMTHF Do?
Founded in 2009 and headquartered in Hangzhou, China, Venus Medtech (Hangzhou) Inc. is dedicated to the development and commercialization of transcatheter heart valve medical devices. The company's initial focus was on addressing the unmet needs in the treatment of valvular heart diseases in China. Its flagship product, VenusA-Valve, is a transcatheter aortic heart valve replacement (TAVR) device designed to treat severe aortic stenosis, a condition characterized by the narrowing of the aortic valve. This product marked a significant advancement in minimally invasive heart valve replacement procedures in the region. Over the years, Venus Medtech has expanded its product portfolio to include VenusP-Valve, a transcatheter pulmonary valve system for treating right ventricular outflow tract dysfunction. Additionally, the company offers V8/TAV8 balloon aortic valvuloplasty catheter systems and TriGUARD3, a cerebral embolic protection device aimed at minimizing the risk of brain damage during TAVR and other structural heart disease surgeries. The company is also developing VenusA-Plus and VenusA-Pilot, next-generation TAVR product candidates, and exploring transcatheter solutions for mitral and tricuspid valve replacement. Furthermore, Venus Medtech is involved in developing the Liwen RF ablation system for hypertrophic cardiomyopathy and renal denervation for hypertension treatment. Venus Medtech's geographic reach extends beyond Mainland China, with international operations aimed at expanding the availability of its innovative medical devices. The company competes with other medical device manufacturers in the cardiovascular space, focusing on technological innovation and clinical efficacy to maintain its market position.
What Products and Services Does VMTHF Offer?
- Develops and commercializes transcatheter aortic heart valve replacement (TAVR) products.
- Offers solutions for treating severe aortic stenosis with the VenusA-Valve.
- Provides transcatheter pulmonary valve systems (VenusP-Valve) for right ventricular outflow tract dysfunction.
- Manufactures balloon aortic valvuloplasty catheter systems (V8/TAV8).
- Offers cerebral embolic protection devices (TriGUARD3) to minimize brain damage during heart surgeries.
- Develops next-generation TAVR product candidates like VenusA-Plus and VenusA-Pilot.
- Explores transcatheter mitral and tricuspid valve replacement technologies.
- Develops ablation systems for hypertrophic cardiomyopathy and renal denervation for hypertension.
How Does VMTHF Make Money?
- Develops and manufactures transcatheter heart valve medical devices.
- Sells its products directly to hospitals and clinics in Mainland China and internationally.
- Generates revenue from the sale of VenusA-Valve, VenusP-Valve, and other related devices.
- Invests in research and development to create innovative cardiovascular solutions.
What Industry Does VMTHF Operate In?
Venus Medtech operates within the global medical device industry, specifically focusing on the cardiovascular segment. The market for transcatheter heart valves is experiencing substantial growth, driven by the increasing prevalence of valvular heart diseases and the preference for minimally invasive procedures. Competitors include established players like BCCOY (Boston Scientific), CLLKF (Edwards Lifesciences), and DMTRF (Medtronic), as well as emerging companies in the Chinese market. The industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. Venus Medtech aims to differentiate itself through innovation, clinical evidence, and a strong presence in the Chinese market.
Who Are VMTHF's Key Customers?
- Hospitals and clinics specializing in cardiovascular care.
- Interventional cardiologists and cardiac surgeons.
- Patients with severe aortic stenosis, pulmonary valve dysfunction, and other heart conditions.
- Healthcare providers seeking minimally invasive treatment options.
VMTHF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that key stakeholders believe in its growth potential.
- Community sentiment has shifted positively as discussions around innovative product developments have gained traction.
- The market is increasingly recognizing Venus Medtech's role in the evolving healthcare landscape, particularly in cardiovascular solutions.
- Recent partnerships and collaborations have sparked optimism about the company’s ability to expand its market presence.
Bear Case
- Concerns about competition in the medical device sector have surfaced, with some analysts questioning Venus Medtech's ability to maintain its edge.
- Negative sentiment from a segment of the trading community highlights worries about regulatory hurdles impacting product approvals.
- Recent criticisms regarding the company’s financial transparency may lead to skepticism among potential investors.
- Market reactions to broader economic conditions suggest caution, as investors weigh potential impacts on healthcare spending.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VMTHF Latest News
No recent news available for VMTHF.
VMTHF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VMTHF.
Price Targets
Wall Street price target analysis for VMTHF.
VMTHF MoonshotScore
What does this score mean?
The MoonshotScore rates VMTHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Hou-Sen Lim MEng.
CEO
Hou-Sen Lim holds a MEng. and has extensive experience in the medical device industry. His background includes leadership roles in various healthcare companies, focusing on strategic planning, product development, and commercialization. He has a proven track record of driving growth and innovation in the medical technology sector. His expertise spans across multiple therapeutic areas, including cardiovascular, orthopedic, and surgical devices. He is known for his ability to build and lead high-performing teams and his commitment to improving patient outcomes through innovative medical solutions.
Track Record: Under Hou-Sen Lim's leadership, Venus Medtech has expanded its product portfolio and strengthened its position in the Chinese market. Key achievements include the successful commercialization of VenusA-Valve and VenusP-Valve, as well as the development of next-generation TAVR product candidates. He has also overseen the company's expansion into new therapeutic areas and geographic markets. His strategic decisions have been instrumental in driving the company's growth and innovation.
VMTHF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Venus Medtech (Hangzhou) Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies often have less stringent listing requirements, resulting in increased risks for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for low trading volume and liquidity.
- Higher price volatility compared to exchange-listed stocks.
- Increased risk of fraud or manipulation.
- Lack of regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their track record.
- Research the company's products and services and their market potential.
- Evaluate the company's competitive landscape and its position within the industry.
- Determine the company's ownership structure and any potential conflicts of interest.
- Consult with a financial advisor or conduct independent research before investing.
- Understand the risks associated with investing in OTC stocks.
- Development and commercialization of innovative medical devices.
- Presence in the growing transcatheter heart valve market.
- Experienced management team.
- Operations in Mainland China and internationally.
Venus Medtech (Hangzhou) Inc. Healthcare Stock: Key Questions Answered
What does Venus Medtech (Hangzhou) Inc. do?
Venus Medtech (Hangzhou) Inc. specializes in the development, manufacturing, and commercialization of minimally invasive heart valve replacement devices. Their primary focus is on transcatheter aortic valve replacement (TAVR) and transcatheter pulmonary valve replacement (TPVR) technologies. The company's flagship products, such as the VenusA-Valve and VenusP-Valve, are designed to treat severe aortic stenosis and pulmonary valve dysfunction, respectively. They also offer cerebral embolic protection devices like TriGUARD3 to minimize the risk of stroke during TAVR procedures. Venus Medtech aims to provide innovative cardiovascular solutions to improve patient outcomes and expand access to advanced medical technologies.
What are the main risks for VMTHF?
The main risks for Venus Medtech (Hangzhou) Inc. include intense competition from established medical device companies like Boston Scientific, Edwards Lifesciences, and Medtronic, which have greater resources and market presence. Regulatory hurdles and approval delays for new products can also impact the company's growth prospects. Technological obsolescence is another risk, requiring continuous innovation to maintain a competitive edge. Additionally, the company's negative profit margin poses a challenge, as it needs to achieve profitability to sustain its operations. Operating in the Chinese market also entails regulatory and economic uncertainties.
What are the key factors to evaluate for VMTHF?
Venus Medtech (Hangzhou) Inc. (VMTHF) holds an AI score of 57/100 (moderate). Not financial advice.
How frequently does VMTHF data refresh on this page?
VMTHF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven VMTHF's recent stock price performance?
Venus Medtech (Hangzhou) Inc. (VMTHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative transcatheter heart valve technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VMTHF overvalued or undervalued right now?
Valuing Venus Medtech (Hangzhou) Inc. (VMTHF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying VMTHF?
Before investing in Venus Medtech (Hangzhou) Inc. (VMTHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding VMTHF to a portfolio?
Key strength of Venus Medtech (Hangzhou) Inc. (VMTHF): Innovative transcatheter heart valve technologies. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage due to OTC listing.
- Financial data based on available public information.
- OTC market carries inherent risks.